• License expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease
• Agreement builds on Company's expertise in vector-borne diseases and complements ongoing development of tafenoquine for babesiosis
• Company continues to evaluate multiple regulatory pathways for castanospermine while prioritizing prescription drug development

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.